Blood - Google Scholar Metrics

h5-index:152
h5-median:202

h5-index is the h-index for articles published in the last 5 complete years. It is the largest number h such that h articles published in 2014-2018 have at least h citations each.hide

h5-median for a publication is the median number of citations for the articles that make up its h5-index.hide

#1 Hematology
#14 Health & Medical Sciences

Title / Author	Cited by	Year
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia DA Arber, A Orazi, R Hasserjian, J Thiele, MJ Borowitz, MM Le Beau, ... Blood 127 (20), 2391-2405	2775	2016
The 2016 revision of the World Health Organization classification of lymphoid neoplasms SH Swerdlow, E Campo, SA Pileri, NL Harris, H Stein, R Siebert, ... Blood 127 (20), 2375-2390	2420	2016
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel H Döhner, E Estey, D Grimwade, S Amadori, FR Appelbaum, T Büchner, ... Blood 129 (4), 424-447	965	2017
A systematic analysis of global anemia burden from 1990 to 2010 NJ Kassebaum, R Jasrasaria, M Naghavi, SK Wulf, N Johns, R Lozano, ... Blood 123 (5), 615-624	771	2014
Current concepts in the diagnosis and management of cytokine release syndrome DW Lee, R Gardner, DL Porter, CU Louis, N Ahmed, M Jensen, SA Grupp, ... Blood 124 (2), 188-195	707	2014
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes DP Steensma, R Bejar, S Jaiswal, RC Lindsley, MA Sekeres, ... Blood 126 (1), 9-16	586	2015
Antibody-modified T cells: CARs take the front seat for hematologic malignancies MV Maus, SA Grupp, DL Porter, CH June Blood 123 (17), 2625-2635	566	2014
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib JC Byrd, RR Furman, SE Coutre, JA Burger, KA Blum, M Coleman, ... Blood 125 (16), 2497-2506	542	2015
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia JR Brown, JC Byrd, SE Coutre, DM Benson, IW Flinn, ... Blood 123 (22), 3390-3397	480	2014
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with> 30% blasts H Dombret, JF Seymour, A Butrym, A Wierzbowska, D Selleslag, JH Jang, ... Blood 126 (3), 291-299	439	2015
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era Z Zhou, LH Sehn, AW Rademaker, LI Gordon, AS LaCasce, ... Blood 123 (6), 837-842	432	2014
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes E Rumi, D Pietra, V Ferretti, T Klampfl, AS Harutyunyan, JD Milosevic, ... Blood 123 (10), 1544-1551	420	2014
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials N van Es, M Coppens, S Schulman, S Middeldorp, HR Büller Blood 124 (12), 1968-1975	375	2014
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms P Lundberg, A Karow, R Nienhold, R Looser, H Hao-Shen, I Nissen, ... Blood 123 (14), 2220-2228	363	2014
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia SL Maude, DT Teachey, DL Porter, SA Grupp Blood 125 (26), 4017-4023	353	2015
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages JF Emile, O Abla, S Fraitag, A Horne, J Haroche, J Donadieu, ... Blood 127 (22), 2672-2681	347	2016
GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity MA Spinner, LA Sanchez, AP Hsu, PA Shaw, CS Zerbe, KR Calvo, ... Blood 123 (6), 809-821	332	2014
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial K Fischer, J Bahlo, AM Fink, V Goede, CD Herling, P Cramer, ... Blood 127 (2), 208-215	330	2016
Thrombosis: tangled up in NETs K Martinod, DD Wagner Blood 123 (18), 2768-2776	330	2014
Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry J Beyer-Westendorf, K Förster, S Pannach, F Ebertz, V Gelbricht, ... Blood 124 (6), 955-962	327	2014

1 - 20

Dates and citation counts are estimated and are determined automatically by a computer program.